



# Combat Drugs Limited

Regd. Off: 4<sup>th</sup> Floor, Plot No. 94,  
Sagar Society, Road No.2,  
Banjara Hills, Hyderabad – 500 034  
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,  
Road No. 14, Gayatri Nagar,  
Bouduppal, Hyd - 500039, T.S  
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100  
Url: www.combatdrugs.in  
Email: info@combatdrugs.in  
GST:36AAACC8372L1ZB

23<sup>rd</sup> July, 2018

To,  
The General Manager  
Department of Corporate Services - CRD  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai 400 001

Dear Sir,

## **Sub: Outcome of Board Meeting – Quarterly Results**

Dear Sir,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and all other applicable provisions and with reference to our letter dated 14<sup>th</sup> July, 2018, this is to inform you that the meeting of the Board of Directors of the company was held today ie; 23<sup>rd</sup> July, 2018 at 12.00 P.M and concluded at 02.00 P.M., wherein the Board of directors of the company approved the Un-Audited Financial Results (Stand Alone and Consolidated ) for the quarter Ended 30<sup>th</sup> June, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- 1) Statement of Un-Audited Financial Results (Standalone and Consolidated) for the quarter Ended 30<sup>th</sup> June, 2018.
- 2) Auditors Report on Financial Results (Standalone and Consolidated).

We kindly request you to take the same on record.

Your Sincerely,

For **COMBAT DRUGS LIMITED**

SUSHANT MOHAN LAL

**(DIRECTOR & COMPLIANCE OFFICER)**



**COMBAT DRUGS LIMITED** (CIN CL23230TG1986PLC006781)

Regd Office : 4th Floor, Plot No.94, Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2018**

All amounts in ₹ Lakhs, unless otherwise stated

Sl.No.	Particulars	Quarter ended			Year ended	
		30-Jun-18	31-Mar-18	30-Jun-17	31-Mar-18	
		Unaudited	Audited	Unaudited	Audited	
1	Revenue from Operations	485.60	31.77	3.59	50.42	
2	Other Income	-	11.54	-	62.58	
3	<b>Total income (1+2)</b>	<b>485.60</b>	<b>43.31</b>	<b>3.59</b>	<b>113.00</b>	
4	<b>Expenses</b>					
a.	Cost of Materials consumed	480.32	30.49	0.80	43.42	
b.	Changes in Inventories of Finished Goods, work -in-progress and stock-in-trade	(9.75)	(3.50)	-	(2.70)	
c.	Employee Benefits Expense	4.35	1.99	5.85	24.94	
d.	Other Expenses	3.27	11.61	4.71	29.10	
	<b>Total Expenses</b>	<b>478.19</b>	<b>40.59</b>	<b>11.36</b>	<b>94.76</b>	
5	Profit Before exceptional items and tax (3-4)	7.41	2.72	(7.77)	18.24	
6	Exceptional Items	-	-	-	-	
7	<b>Profit Before Tax (5-6)</b>	<b>7.41</b>	<b>2.72</b>	<b>(7.77)</b>	<b>18.24</b>	
8	<b>Tax Expenses</b>					
a.	Current tax	-	-	-	-	
b.	Deferred tax	-	-	-	-	
	Total tax	-	-	-	-	
9	Net Profit / (Loss) for the period (7-8)	7.41	2.72	(7.77)	18.24	
10	Other comprehensive income, (net of tax)	-	-	-	-	
11	<b>Total comprehensive income for the period (9-10)</b>	<b>7.41</b>	<b>2.72</b>	<b>(7.77)</b>	<b>18.24</b>	
12	Paid-up equity share capital (Face Value of Rs. 10/- each)	800.00	800.00	800.00	800.00	
13	Earnings Per Share (EPS) (Basic & Diluted)	0.09	0.03	(0.10)	0.23	

**Notes :**

- The operations of the Company relate to only one segment viz., Pharmaceuticals and hence segment reporting is not applicable.
- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 23.07.2018.
- The figures of previous periods have been regrouped wherever necessary.

For and on behalf of the Board of Directors of  
**Combat Drugs Limited**



**Director**

**Place: Hyderabad**

**Date:23.07.2018**

**COMBAT DRUGS LIMITED** (CIN CL23230TG1986PLC006781)

Regd Office : 4th Floor, Plot No.94, Sagar society, Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2018**

All amounts in ₹ Lakhs, unless otherwise stated

Sl.No.	Particulars	Quarter ended		Year ended
		30-Jun-18	31-Mar-18	31-Mar-18
		Consolidated	Audited	Audited
1	Revenue from Operations	486.26	31.77	50.42
2	Other Income	-	11.54	62.58
3	<b>Total income (1+2)</b>	<b>486.26</b>	<b>43.31</b>	<b>113.00</b>
4	<b>Expenses</b>			
a.	Cost of Materials consumed	480.32	30.49	43.42
b.	Changes in Inventories of Finished Goods, work -in-progress and stock-in-trade	(9.75)	(3.50)	(2.70)
c.	Employee Benefits Expense	4.35	1.99	24.94
d.	Finance Charges	0.18	-	-
e.	Other Expenses	3.33	11.61	29.10
	<b>Total Expenses</b>	<b>478.42</b>	<b>40.59</b>	<b>94.76</b>
5	Profit Before exceptional items and tax (3-4)	7.84	2.72	18.24
6	Exceptional Items	-	-	-
7	<b>Profit Before Tax (5-6)</b>	<b>7.84</b>	<b>2.72</b>	<b>18.24</b>
8	<b>Tax Expenses</b>			
a.	Current tax	-	-	-
b.	Deferred tax	-	-	-
	Total tax	-	-	-
9	Net Profit / (Loss) for the period (7-8)	<b>7.84</b>	<b>2.72</b>	<b>18.24</b>
10	Other comprehensive income, (net of tax)	-	-	-
11	<b>Total comprehensive income for the period (9-10)</b>	<b>7.84</b>	<b>2.72</b>	<b>18.24</b>
12	Paid-up equity share capital (Face Value of Rs. 10/- each)	800.00	800.00	800.00
13	Earnings Per Share (EPS) (Basic & Diluted)	0.10	0.03	0.23

**Notes :**

- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 23.07.2018.
- The Operations of the Group relate to Holding company Combat Drugs Limited and its Subsidiaries RA Labs PTE Ltd, Singapore and ICP Solutions Private Limited, India.
- The operations of the Group relate to only one segment viz., Pharmaceuticals and hence segment reporting is not applicable.
- Consolidated financial results are applicable from Quarter ended 31st March, 2018.
- The figures of previous periods have been regrouped wherever necessary.

For and on behalf of the Board of Directors of  
**Combat Drugs Limited**


Director

Place : Hyderabad

Date: 23.07.2018

**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF  
INTERIM FINANCIAL STATEMENTS**

To

The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying statement of Consolidated Unaudited Financial results of Combat Drugs Limited ("Holding Company") and its wholly owned subsidiary companies namely RA Labs PTE Ltd and ICP Solutions Private Limited., (together referred to as "the Group"), for the quarter ended 30<sup>th</sup> June, 2018 ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/CMD/15/2015 dated 30<sup>th</sup> November, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes financial results and other financial information of the wholly owned subsidiary RA Labs PTE Ltd, Singapore which reflect total revenues of Rs. 0.66 lakhs, total net profit of Rs. 0.43 lakhs and total comprehensive income of Rs. Nil for the quarter ended 30<sup>th</sup> June, 2018. Such financial information has been prepared in accordance with accounting principles generally accepted in its country and which has not been audited and which is certified by the Management. The Management has converted the financial statements of this subsidiaries from accounting principles generally accepted in its country to accounting principles generally accepted in India. In our opinion and according to the information and explanations given to us by the



7 'A', SURYATOWERS, SARDAR PATEL ROAD, SECUNDERABAD - 500 003.  
PHONE : 2781 2377, 2781 2034, FAX : 2781 2091



Management, these financial results and other financial information are not material to the Group. Our opinion is not modified in respect of this matter.

Based on our review conducted as above and based on the consideration of the unaudited interim financial information of the subsidiaries which have been furnished by the Management referred to in paragraph above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Secunderabad  
Date: 23.07.2018



For M.Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.0001255)

A handwritten signature in blue ink, appearing to read "A.V. Sadasiva".

A.V.Sadasiva  
Partner

M.No: 018404

**M. ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF  
INTERIM FINANCIAL STATEMENTS**

To  
The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Combat Drugs Limited for the quarter ended 30<sup>th</sup> June, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information* performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Secunderabad  
Date: 23.07.2018



For M.Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.0001255)

A.V.Sadasiva  
Partner

M.No: 018404